[HTML][HTML] Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review
The absorption of oral drugs is frequently plagued by significant variability with potentially
serious therapeutic consequences. The source of variability can be traced back to …
serious therapeutic consequences. The source of variability can be traced back to …
Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory, industrial and academic perspective
W Lin, Y Chen, JD Unadkat, X Zhang, D Wu… - Pharmaceutical …, 2022 - Springer
Several regulatory guidances on the use of physiologically based pharmacokinetic (PBPK)
analyses and physiologically based biopharmaceutics model (s)(PBBM (s)) have been …
analyses and physiologically based biopharmaceutics model (s)(PBBM (s)) have been …
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery
Many lead compounds fail to reach clinical trials despite being potent because of low
bioavailability attributed to their insufficient solubility making solubility a primary and crucial …
bioavailability attributed to their insufficient solubility making solubility a primary and crucial …
[HTML][HTML] Oral drug delivery strategies for development of poorly water soluble drugs in paediatric patient population
S Salunke, F O'Brien, DCT Tan, D Harris… - Advanced Drug Delivery …, 2022 - Elsevier
Selecting the appropriate formulation and solubility-enabling technology for poorly water
soluble drugs is an essential element in the development of formulations for paediatric …
soluble drugs is an essential element in the development of formulations for paediatric …
[HTML][HTML] Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
LFM Verscheijden, JB Koenderink, TN Johnson… - Pharmacology & …, 2020 - Elsevier
Developmental changes in children can affect the disposition and clinical effects of a drug,
indicating that scaling an adult dose simply down per linear weight can potentially lead to …
indicating that scaling an adult dose simply down per linear weight can potentially lead to …
Release mechanisms and applications of drug delivery systems for extended-release
Introduction Drug delivery systems with extended-release profiles are ideal in improving
patient compliance with enhanced efficacy. To develop devices capable of a prolonged …
patient compliance with enhanced efficacy. To develop devices capable of a prolonged …
Review of paediatric gastrointestinal physiology relevant to the absorption of orally administered medicines
E Wollmer, AL Ungell, JM Nicolas, S Klein - Advanced drug delivery …, 2022 - Elsevier
Despite much progress in regulations to improve paediatric drug development, there
remains a significant need to develop better medications for children. For the design of oral …
remains a significant need to develop better medications for children. For the design of oral …
Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List
RS Meyers, J Thackray, KL Matson… - The Journal of …, 2020 - meridian.allenpress.com
OBJECTIVES The safe use of medications in pediatric patients requires practitioners to
consider the unique pharmacokinetics and pharmacodynamics of drugs prescribed in this …
consider the unique pharmacokinetics and pharmacodynamics of drugs prescribed in this …
Off‐label, but on‐evidence? A review of the level of evidence for pediatric pharmacotherapy
TM van der Zanden, NJL Smeets… - Clinical …, 2022 - Wiley Online Library
Many drugs are still prescribed off‐label to the pediatric population. Although off‐label drug
use not supported by high level of evidence is potentially harmful, a comprehensive …
use not supported by high level of evidence is potentially harmful, a comprehensive …
Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy
Ruthenium complex is an important compound group for antitumor drug research and
development. NAMI-A, KP1019, TLD1433 and other ruthenium complexes have entered …
development. NAMI-A, KP1019, TLD1433 and other ruthenium complexes have entered …